Lasmiditan
REYVOW
What it isSelective 5-HT1F-receptor agonist; acute migraine.
Why this oneIt treats migraine without vasoconstriction, making it an option when vascular disease rules out triptans.
What limits itDriving is prohibited for eight hours after a dose because impairment persists; dizziness and paresthesia are common. Schedule V.
FDA-approved for
- acute migraine (2019)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Acute migraine (with/without aura) | Adults | 50, 100, or 200 mg PRN | 50-200 mg PRN | One dose/24h; ≤4 attacks/30 days |
Renal Undefined
Hepatic Severe hepatic impairment (Child-Pugh C): not recommended (not studied)
A second dose is not effective for the same attack; no more than one dose per 24 hours
Instructions
- Swallow tablets whole; do not split, crush, or chew
- May take with or without food
- Do not drive or operate machinery for at least 8 hours after each dose
Cautions
- Significant driving impairment (≥8 h)
- CNS depression (caution with alcohol/other CNS depressants)
- MAOIs due to risk of serotonin syndrome
- Medication overuse headache
Adverse reactions
- Dizziness
- Fatigue
- Paresthesia
- Sedation
Pregnancy No adequate human data; animal studies show fetal harm
Lactation No human data; present in rat milk (~3× maternal plasma)
NO BOXED WARNINGS
Principal riskDriving prohibited for eight hours after a dose
Cost, est. cash$500–$1,200/month
Generic entry2037 est.
Classes and tags
Clinical profile
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityAgent-specific vascular, serotonergic or hepatic risks; acute overdose is usually limited outside ergot or cardiovascular agents.
Mechanism of action: Lasmiditan ballicule
Open Lasmiditan in the interactive console ↗
Memory aids: mascots and interaction avatars
